Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Nimacimab

CBeyond

Skye Bioscience · Phase 2 · Active, not recruiting · Enrollment 136

NCT06577090

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Nimacimab injectionn/rn/rn/rn/r
Nimacimab placebo injectionn/rn/rn/rn/r
Semaglutide injection + Nimacimab injection 200 mgn/rn/rn/rn/r
Semaglutide injection + Nimacimab placebo injectionn/rn/rn/rn/r
Open-label 300 mg Nimacimab injection (study extension)n/rn/rn/rn/r

Not shown

  • Nimacimab injection: endpoint not reported
  • Nimacimab placebo injection: endpoint not reported
  • Semaglutide injection + Nimacimab injection 200 mg: endpoint not reported
  • Semaglutide injection + Nimacimab placebo injection: endpoint not reported
  • Open-label 300 mg Nimacimab injection (study extension): endpoint not reported